Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김희선 | * |
dc.date.accessioned | 2016-08-28T12:08:28Z | - |
dc.date.available | 2016-08-28T12:08:28Z | - |
dc.date.issued | 2012 | * |
dc.identifier.issn | 1043-6618 | * |
dc.identifier.other | OAK-8843 | * |
dc.identifier.uri | https://dspace.ewha.ac.kr/handle/2015.oak/222701 | - |
dc.description.abstract | Matrix metalloproteinases (MMPs) are zinc-dependent endopeptidases which play a key role in invasion, migration, and angiogenesis of astrogliomas and other malignant tumors. Thus, controlling MMPs has been considered an important therapeutic strategy for prevention and/or treatment of gliomas. However, most MMP inhibitors developed so far are broad spectrum inhibitors; thus, it is necessary to develop a selective MMP inhibitor to minimize potential side effects. In the present study, we found that mangiferin, a glucosylxanthone isolated from Anemarrhena asphodeloides, specifically inhibited MMP-9 gene expression in phorbol myristate acetate (PMA)-stimulated human astroglioma U87MG, U373MG, and CRT-MG cells. However, it did not affect other MMPs, such as MMP-1, -2, -3, and -14. Mangiferin suppressed MMP-9 expression at the promoter, mRNA, and protein levels and additionally inhibited MMP-9 enzymatic activity. The Matrigel-invasion assay showed that mangiferin suppresses the in vitro invasiveness of glioma cells, which appears to be correlated with mangiferin-mediated MMP-9 inhibition. Further mechanistic studies demonstrated that mangiferin inhibits the binding of NF-κB and AP-1 to the MMP-9 promoter and suppresses the PMA-induced phosphorylation of Akt and MAP kinases, which are upstream signaling molecules in MMP-9 expression. Thus, the specific inhibition of MMP-9 by mangiferin may provide a valuable pharmacological tool for treatment of gliomas. © 2012 Elsevier Ltd. | * |
dc.language | English | * |
dc.title | Selective inhibition of MMP-9 gene expression by mangiferin in PMA-stimulated human astroglioma cells: Involvement of PI3K/Akt and MAPK signaling pathways | * |
dc.type | Article | * |
dc.relation.issue | 1 | * |
dc.relation.volume | 66 | * |
dc.relation.index | SCI | * |
dc.relation.index | SCIE | * |
dc.relation.index | SCOPUS | * |
dc.relation.startpage | 95 | * |
dc.relation.lastpage | 103 | * |
dc.relation.journaltitle | Pharmacological Research | * |
dc.identifier.doi | 10.1016/j.phrs.2012.02.013 | * |
dc.identifier.wosid | WOS:000304569600011 | * |
dc.identifier.scopusid | 2-s2.0-84860437626 | * |
dc.author.google | Jung J.-S. | * |
dc.author.google | Jung K. | * |
dc.author.google | Kim D.-H. | * |
dc.author.google | Kim H.-S. | * |
dc.contributor.scopusid | 김희선(57191372551) | * |
dc.date.modifydate | 20240118140922 | * |